Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen: Replicating and shielding viral DNA during viral persistence

Journal of Virology

Volumn 91, Issue 14, 2017, Pages

  Weidner Glunde, Magdalena ^a,b   Mariggiò, Giuseppe ^a,b   Schulz, Thomas F ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Cytoplasmic DNA sensors; Cytoplasmic variants; Kaposi's sarcoma associated herpesvirus; LANA speckles; Structure; Virus persistence

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; VIRUS DNA; LATENCY-ASSOCIATED NUCLEAR ANTIGEN; NUCLEAR PROTEIN; VIRUS ANTIGEN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DISEASE ASSOCIATION; DNA BINDING; DNA REPLICATION; FLUORESCENCE ANALYSIS; HERPESVIRIDAE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; KAPOSI SARCOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS LATENCY; VIRUS REPLICATION; WESTERN BLOTTING; BIOLOGICAL MODEL; CHEMISTRY; HUMAN HERPESVIRUS 8; METABOLISM; MOLECULAR MODEL; PHYSIOLOGY; PROTEIN CONFORMATION;

ANTIGENS, VIRAL; DNA REPLICATION; DNA, VIRAL; HERPESVIRUS 8, HUMAN; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN CONFORMATION; VIRUS LATENCY;

EID: 85021210997     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01083-16     Document Type: Article

References (113)

1. Grundhoff A, Ganem D. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113:124-136. https://doi.org/10 .1172/JCI200417803
2. Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. 1996. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88:2648-2654
3. Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. 1995. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86:2708-2714
4. Juillard F, Tan M, Li S, Kaye KM. 2016. Kaposi's sarcoma herpesvirus genome persistence. Front Microbiol 7:1149. https://doi.org/10.3389/fmicb.2016.01149
5. Purushothaman P, Dabral P, Gupta N, Sarkar R, Verma SC. 2016. KSHV genome replication and maintenance. Front Microbiol 7:54. https://doi .org/10.3389/fmicb.2016.00054
6. Uppal T, Banerjee S, Sun Z, Verma SC, Robertson ES. 2014. KSHV LANA-the master regulator of KSHV latency. Viruses 6:4961-4998. https://doi.org/10.3390/v6124961
7. Wei F, Gan J, Wang C, Zhu C, Cai Q. 2016. Cell cycle regulatory functions of the KSHV oncoprotein LANA. Front Microbiol 7:334. https://doi.org/10.3389/fmicb.2016.00334
8. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 2:925-928. https://doi.org/10.1038/nm0896-925
9. Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. 1996. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcomaassociated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 2:918-924. https://doi.org/10.1038/nm0896-918
10. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 70:549-558
11. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard MR, Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A, Tedder RS, Weller IV, Weiss RA, Moore PS. 1996. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 348:1133-1138. https://doi.org/10.1016/S0140-6736(96)07560-5
12. Canham M, Talbot SJ. 2004. A naturally occurring C-terminal truncated isoform of the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus does not associate with viral episomal DNA. J Gen Virol 85:1363-1369. https://doi.org/10.1099/vir.0.79802-0
13. Davis DA, Naiman NE, Wang V, Shrestha P, Haque M, Hu D, Anagho HA, Carey RF, Davidoff KS, Yarchoan R. 2015. Identification of caspase cleavage sites in KSHV latency-associated nuclear antigen and their effects on caspase-related host defense responses. PLoS Pathog 11: e1005064. https://doi.org/10.1371/journal.ppat.1005064
14. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS. 1996. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 335:233-241. https://doi.org/10.1056/NEJM199607253350403
15. Kwun HJ, Toptan T, Ramos da Silva S, Atkins JF, Moore PS, Chang Y. 2014. Human DNA tumor viruses generate alternative reading frame proteins through repeat sequence recoding. Proc Natl Acad Sci U S A 111:E4342-E4349. https://doi.org/10.1073/pnas.1416122111
16. Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, Herrington CS, Moore PS, Schulz TF. 1997. The 222-to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latencyassociated nuclear antigen. J Virol 71:5915-5921
17. Toptan T, Fonseca L, Kwun HJ, Chang Y, Moore PS. 2013. Complex alternative cytoplasmic protein isoforms of the Kaposi's sarcomaassociated herpesvirus latency-associated nuclear antigen 1 generated through noncanonical translation initiation. J Virol 87:2744-2755. https://doi.org/10.1128/JVI.03061-12
18. Kedes DH, Lagunoff M, Renne R, Ganem D. 1997. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest 100:2606-2610. https://doi.org/10.1172/JCI119804
19. Kellam P, Boshoff C, Whitby D, Matthews S, Weiss RA, Talbot SJ. 1997. Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol 1:19-29
20. Pearce M, Matsumura S, Wilson AC. 2005. Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcomaassociated herpesvirus originate from a common promoter. J Virol 79:14457-14464. https://doi.org/10.1128/JVI.79.22.14457-14464.2005
21. Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, Ganem D. 1999. A complex translational program generates multiple novel pro-teins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol 73:5722-5730
22. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 72:1005-1012
23. Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. 1998. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 72:8309-8315
24. Sarid R, Wiezorek JS, Moore PS, Chang Y. 1999. Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol 73: 1438-1446
25. Talbot SJ, Weiss RA, Kellam P, Boshoff C. 1999. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology 257:84-94. https://doi .org/10.1006/viro.1999.9672
26. Hilton IB, Dittmer DP. 2012. Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol 86:9683-9695. https://doi.org/10.1128/JVI.00881-12
27. Matsumura S, Fujita Y, Gomez E, Tanese N, Wilson AC. 2005. Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus by the lytic switch protein RTA (ORF50). J Virol 79:8493-8505. https://doi .org/10.1128/JVI.79.13.8493-8505.2005
28. Ballestas ME, Chatis PA, Kaye KM. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641-644. https://doi.org/10.1126/science.284.5414 .641
29. Barbera AJ, Ballestas ME, Kaye KM. 2004. The Kaposi's sarcomaassociated herpesvirus latency-associated nuclear antigen 1 N terminus is essential for chromosome association, DNA replication, and episome persistence. J Virol 78:294-301. https://doi.org/10.1128/JVI.78.1.294-301.2004
30. Cotter MA, II, Robertson ES. 1999. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology 264:254-264. https://doi.org/10.1006/viro.1999.9999
31. Alkharsah KR, Schulz TF. 2012. A role for the internal repeat of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen in the persistence of an episomal viral genome. J Virol 86:1883-1887. https://doi.org/10.1128/JVI.06029-11
32. De León Vázquez E, Kaye KM. 2011. The internal Kaposi's sarcomaassociated herpesvirus LANA regions exert a critical role on episome persistence. J Virol 85:7622-7633. https://doi.org/10.1128/JVI.00304-11
33. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. 2005. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105:2510-2518. https://doi.org/10.1182/blood-2004-08-3052
34. Li Q, Zhou F, Ye F, Gao SJ. 2008. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology 379:234-244. https://doi.org/10.1016/j.virol.2008 .06.043
35. Zhang YJ, Wang KY, Stein DA, Patel D, Watkins R, Moulton HM, Iversen PL, Matson DO. 2007. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus by morpholino oligomers. Antiviral Res 73: 12-23. https://doi.org/10.1016/j.antiviral.2006.05.017
36. Ballestas ME, Kaye KM. 2001. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J Virol 75:3250-3258. https://doi.org/10.1128/JVI.75.7.3250-3258.2001
37. Grundhoff A, Ganem D. 2003. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids. J Virol 77:2779-2783. https://doi.org/10 .1128/JVI.77.4.2779-2783.2003
38. Hu J, Garber AC, Renne R. 2002. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol 76:11677-11687. https://doi.org/10.1128/JVI.76.22.11677-11687.2002
39. Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Joukov V, Walter JC, Luger K, Kaye KM. 2006. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311:856-861. https://doi.org/10.1126/science.1120541
40. Garber AC, Shu MA, Hu J, Renne R. 2001. DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 75:7882-7892. https://doi .org/10.1128/JVI.75.17.7882-7892.2001
41. Stedman W, Deng Z, Lu F, Lieberman PM. 2004. ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol 78:12566-12575. https://doi.org/10.1128/JVI .78.22.12566-12575.2004
42. Verma SC, Choudhuri T, Kaul R, Robertson ES. 2006. Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol 80:2243-2256. https://doi .org/10.1128/JVI.80.5.2243-2256.2006
43. Sun Q, Tsurimoto T, Juillard F, Li L, Li S, De Leon Vazquez E, Chen S, Kaye K. 2014. Kaposi's sarcoma-associated herpesvirus LANA recruits the DNA polymerase clamp loader to mediate efficient replication and virus persistence. Proc Natl Acad Sci U S A 111:11816-11821. https://doi.org/10.1073/pnas.1404219111
44. Purushothaman P, McDowell ME, McGuinness J, Salas R, Rumjahn SM, Verma SC. 2012. Kaposi's sarcoma-associated herpesvirus-encoded LANA recruits topoisomerase IIbeta for latent DNA replication of the terminal repeats. J Virol 86:9983-9994. https://doi.org/10.1128/JVI .00839-12
45. Dheekollu J, Chen HS, Kaye KM, Lieberman PM. 2013. Timelessdependent DNA replication-coupled recombination promotes Kaposi's sarcoma-associated herpesvirus episome maintenance and terminal repeat stability. J Virol 87:3699-3709. https://doi.org/10.1128/JVI.02211-12
46. Hu J, Yang Y, Turner PC, Jain V, McIntyre LM, Renne R. 2014. LANA binds to multiple active viral and cellular promoters and associates with the H3K4methyltransferase hSET1 complex. PLoS Pathog 10:e1004240. https://doi.org/10.1371/journal.ppat.1004240
47. Lu J, Verma SC, Cai Q, Saha A, Dzeng RK, Robertson ES. 2012. The RBP-Jkappa binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog 8:e1002479. https://doi.org/10.1371/journal.ppat.1002479
48. Mercier A, Arias C, Madrid AS, Holdorf MM, Ganem D. 2014. Site-specific association with host and viral chromatin by Kaposi's sarcomaassociated herpesvirus LANA and its reversal during lytic reactivation. J Virol 88:6762-6777. https://doi.org/10.1128/JVI.00268-14
49. Jeong JH, Orvis J, Kim JW, McMurtrey CP, Renne R, Dittmer DP. 2004. Regulation and autoregulation of the promoter for the latencyassociated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem 279:16822-16831. https://doi.org/10.1074/jbc .M312801200
50. Krithivas A, Young DB, Liao G, Greene D, Hayward SD. 2000. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol 74:9637-9645. https://doi.org/10.1128/JVI.74.20.9637-9645.2000
51. Lim C, Lee D, Seo T, Choi C, Choe J. 2003. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. J Biol Chem 278:7397-7405. https://doi.org/10.1074/jbc.M211912200
52. Ottinger M, Christalla T, Nathan K, Brinkmann MM, Viejo-Borbolla A, Schulz TF. 2006. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4-and BRD2/RING3-induced G1 cell cycle arrest. J Virol 80:10772-10786. https://doi.org/10.1128/JVI.00804-06
53. Platt GM, Simpson GR, Mittnacht S, Schulz TF. 1999. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol 73:9789-9795
54. Shamay M, Krithivas A, Zhang J, Hayward SD. 2006. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcomaassociated herpesvirus LANA. Proc Natl Acad Sci U S A 103: 14554-14559. https://doi.org/10.1073/pnas.0604469103
55. Viejo-Borbolla A, Ottinger M, Bruning E, Burger A, Konig R, Kati E, Sheldon JA, Schulz TF. 2005. Brd2/RING3 interacts with a chromatinbinding domain in the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. J Virol 79:13618-13629. https://doi.org/10.1128/JVI.79.21.13618-13629.2005
56. Jeong J, Papin J, Dittmer D. 2001. Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters. J Virol 75:1798-1807. https://doi.org/10.1128/JVI.75.4.1798-1807.2001
57. Renne R, Barry C, Dittmer D, Compitello N, Brown PO, Ganem D. 2001. Modulation of cellular and viral gene expression by the latencyassociated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 75:458-468. https://doi.org/10.1128/JVI.75.1.458-468.2001
58. An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. 2005. The latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem 280:3862-3874. https://doi.org/10.1074/jbc.M407435200
59. Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, Borris DL, Brady J, Blauvelt A. 2003. Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol 77:6188-6196. https://doi.org/10.1128/JVI.77.11.6188-6196.2003
60. Lu F, Tsai K, Chen HS, Wikramasinghe P, Davuluri RV, Showe L, Domsic J, Marmorstein R, Lieberman PM. 2012. Identification of hostchromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol 86:5752-5762. https://doi .org/10.1128/JVI.07216-11
61. Su L, Liao Q, Wu Y, Chen X. 2011. Kaposi's sarcoma-associated herpesvirusencoded LANA down-regulates IL-22R1 expression through a cis-acting element within the promoter region. PLoS One 6:e19106. https://doi.org/10.1371/journal.pone.0019106
62. Hu J, Liu E, Renne R. 2009. Involvement of SSRP1 in latent replication of Kaposi's sarcoma-associated herpesvirus. J Virol 83:11051-11063. https://doi.org/10.1128/JVI.00907-09
63. Kim KY, Huerta SB, Izumiya C, Wang DH, Martinez A, Shevchenko B, Kung HJ, Campbell M, Izumiya Y. 2013. Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. J Virol 87:6782-6793. https://doi.org/10.1128/JVI.00011-13
64. Lim C, Gwack Y, Hwang S, Kim S, Choe J. 2001. The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem 276:31016-31022. https://doi.org/10.1074/jbc.M102431200
65. Sakakibara S, Ueda K, Nishimura K, Do E, Ohsaki E, Okuno T, Yamanishi K. 2004. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J Virol 78:7299-7310. https://doi.org/10.1128/JVI.78.14.7299-7310.2004
66. Bechtel JT, Winant RC, Ganem D. 2005. Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol 79: 4952-4964. https://doi.org/10.1128/JVI.79.8.4952-4964.2005
67. Günther T, Grundhoff A. 2010. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 6:e1000935. https://doi.org/10.1371/journal.ppat.1000935
68. Toth Z, Maglinte DT, Lee SH, Lee HR, Wong LY, Brulois KF, Lee S, Buckley JD, Laird PW, Marquez VE, Jung JU. 2010. Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 6:e1001013. https://doi.org/10 .1371/journal.ppat.1001013
69. Toth Z, Papp B, Brulois K, Choi YJ, Gao SJ, Jung JU. 2016. LANAmediated recruitment of host polycomb repressive complexes onto the KSHV genome during de novo infection. PLoS Pathog 12:e1005878. https://doi.org/10.1371/journal.ppat.1005878
70. Günther T, Schreiner S, Dobner T, Tessmer U, Grundhoff A. 2014. Influence of ND10 components on epigenetic determinants of early KSHV latency establishment. PLoS Pathog 10:e1004274. https://doi.org/10.1371/journal.ppat.1004274
71. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93:14862-14867. https://doi.org/10.1073/pnas.93.25 .14862
72. Cherezova L, Burnside KL, Rose TM. 2011. Conservation of complex nuclear localization signals utilizing classical and non-classical nuclear import pathways in LANA homologs of KSHV and RFHV. PLoS One 6:e18920. https://doi.org/10.1371/journal.pone.0018920
73. Piolot T, Tramier M, Coppey M, Nicolas JC, Marechal V. 2001. Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol 75:3948-3959. https://doi.org/10.1128/JVI.75.8.3948-3959.2001
74. Lim C, Choi C, Choe J. 2004. Mitotic chromosome-binding activity of latency-associated nuclear antigen 1 is required for DNA replication from terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus. J Virol 78:7248-7256. https://doi.org/10.1128/JVI.78.13.7248-7256.2004
75. Wong LY, Matchett GA, Wilson AC. 2004. Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol 78:10074-10085. https://doi.org/10.1128/JVI.78.18.10074-10085.2004
76. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. 2006. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2:e116. https://doi .org/10.1371/journal.ppat.0020116
77. Kwun HJ, da Silva SR, Qin H, Ferris RL, Tan R, Chang Y, Moore PS. 2011. The central repeat domain 1 of Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) prevents cis MHC class I peptide presentation. Virology 412:357-365. https://doi .org/10.1016/j.virol.2011.01.026
78. Fejér G, Medveczky MM, Horvath E, Lane B, Chang Y, Medveczky PG. 2003. The latency-associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus interacts preferentially with the terminal repeats of the genome in vivo and this complex is sufficient for episomal DNA replication. J Gen Virol 84:1451-1462. https://doi.org/10.1099/vir.0 .18940-0
79. Garber AC, Hu J, Renne R. 2002. Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem 277:27401-27411. https://doi.org/10.1074/jbc.M203489200
80. Kelley-Clarke B, Ballestas ME, Srinivasan V, Barbera AJ, Komatsu T, Harris TA, Kazanjian M, Kaye KM. 2007. Determination of Kaposi's sarcomaassociated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J Virol 81:4348-4356. https://doi.org/10.1128/JVI.01289-06
81. Kelley-Clarke B, De Leon-Vazquez E, Slain K, Barbera AJ, Kaye KM. 2009. Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence. J Virol 83:4326-4337. https://doi.org/10.1128/JVI.02395-08
82. Krithivas A, Fujimuro M, Weidner M, Young DB, Hayward SD. 2002. Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol 76:11596-11604. https://doi.org/10.1128/JVI.76.22.11596-11604.2002
83. Hellert J, Weidner-Glunde M, Krausze J, Richter U, Adler H, Fedorov R, Pietrek M, Ruckert J, Ritter C, Schulz TF, Luhrs T. 2013. A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins. PLoS Pathog 9:e1003640. https://doi.org/10 .1371/journal.ppat.1003640
84. Matsumura S, Persson LM, Wong L, Wilson AC. 2010. The latencyassociated nuclear antigen interacts with MeCP2 and nucleosomes through separate domains. J Virol 84:2318-2330. https://doi.org/10 .1128/JVI.01097-09
85. Si H, Verma SC, Lampson MA, Cai Q, Robertson ES. 2008. Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol 82:6734-6746. https://doi.org/10.1128/JVI .00342-08
86. You J, Srinivasan V, Denis GV, Harrington WJ, Jr, Ballestas ME, Kaye KM, Howley PM. 2006. Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol 80:8909-8919. https://doi.org/10.1128/JVI.00502-06
87. Domsic JF, Chen HS, Lu F, Marmorstein R, Lieberman PM. 2013. Molecular basis for oligomeric-DNA binding and episome maintenance by KSHV LANA. PLoS Pathog 9:e1003672. https://doi.org/10.1371/journal .ppat.1003672
88. Hellert J, Weidner-Glunde M, Krausze J, Lunsdorf H, Ritter C, Schulz TF, Luhrs T. 2015. The 3D structure of Kaposi sarcoma herpesvirus LANA C-terminal domain bound to DNA. Proc Natl Acad Sci U S A 112: 6694-6699. https://doi.org/10.1073/pnas.1421804112
89. Ponnusamy R, Petoukhov MV, Correia B, Custodio TF, Juillard F, Tan M, Pires de Miranda M, Carrondo MA, Simas JP, Kaye KM, Svergun DI, McVey CE. 2015. KSHV but not MHV-68 LANA induces a strong bend upon binding to terminal repeat viral DNA. Nucleic Acids Res 43: 10039-10054
90. Wong LY, Wilson AC. 2005. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA. J Virol 79:13829-13836. https://doi.org/10 .1128/JVI.79.21.13829-13836.2005
91. Verma SC, Lu J, Cai Q, Kosiyatrakul S, McDowell ME, Schildkraut CL, Robertson ES. 2011. Single molecule analysis of replicated DNA reveals the usage of multiple KSHV genome regions for latent replication. PLoS Pathog 7:e1002365. https://doi.org/10.1371/journal.ppat.1002365
92. Zhang G, Chan B, Samarina N, Abere B, Weidner-Glunde M, Buch A, Pich A, Brinkmann MM, Schulz TF. 2016. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc Natl Acad Sci U S A 113:E1034-E1043. https://doi.org/10.1073/pnas.1516812113
93. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V. 2013. cGAS produces a 2=-5=-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380-384. https://doi.org/10.1038/nature12306
94. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE. 2013. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3:1355-1361. https://doi.org/10.1016/j.celrep.2013.05.009
95. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, Serganov AA, Liu Y, Jones RA, Hartmann G, Tuschl T, Patel DJ. 2013. Cyclic [G(2=,5=)pA(3=,5=)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153:1094-1107. https://doi.org/10.1016/j.cell.2013.04.046
96. Mankan AK, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M, Kubarenko AV, Andreeva L, Hopfner KP, Hornung V. 2014. Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J 33:2937-2946. https://doi.org/10.15252/embj.201488726
97. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-791. https://doi.org/10.1126/science.1232458
98. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51:226-235. https://doi .org/10.1016/j.molcel.2013.05.022
99. Ma Z, Jacobs SR, West JA, Stopford C, Zhang Z, Davis Z, Barber GN, Glaunsinger BA, Dittmer DP, Damania B. 2015. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. Proc Natl Acad Sci U S A 112:E4306-E4315. https://doi.org/10.1073/pnas .1503831112
100. Horan KA, Hansen K, Jakobsen MR, Holm CK, Soby S, Unterholzner L, Thompson M, West JA, Iversen MB, Rasmussen SB, Ellermann-Eriksen S, Kurt-Jones E, Landolfo S, Damania B, Melchjorsen J, Bowie AG, Fitzgerald KA, Paludan SR. 2013. Proteasomal degradation of herpes simplex virus capsids in macrophages releases DNA to the cytosol for recognition by DNA sensors. J Immunol 190:2311-2319. https://doi.org/10 .4049/jimmunol.1202749
101. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341:1390-1394. https://doi.org/10.1126/science.1244040
102. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, Garcia-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-695. https://doi.org/10.1038/nature12862
103. Wu JJ, Li W, Shao Y, Avey D, Fu B, Gillen J, Hand T, Ma S, Liu X, Miley W, Konrad A, Neipel F, Sturzl M, Whitby D, Li H, Zhu F. 2015. Inhibition of cGAS DNA sensing by a herpesvirus virion protein. Cell Host Microbe 18:333-344. https://doi.org/10.1016/j.chom.2015.07.015
104. Davis ZH, Verschueren E, Jang GM, Kleffman K, Johnson JR, Park J, Von Dollen J, Maher MC, Johnson T, Newton W, Jager S, Shales M, Horner J, Hernandez RD, Krogan NJ, Glaunsinger BA. 2015. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Mol Cell 57:349-360. https://doi.org/10.1016/j.molcel.2014 .11.026
105. Roth S, Rottach A, Lotz-Havla AS, Laux V, Muschaweckh A, Gersting SW, Muntau AC, Hopfner KP, Jin L, Vanness K, Petrini JH, Drexler I, Leonhardt H, Ruland J. 2014. Rad50-CARD9 interactions link cytosolic DNA sensing to IL-1beta production. Nat Immunol 15:538-545. https://doi .org/10.1038/ni.2888
106. Mariggiò G, Koch S, Zhang G, Weidner-Glunde M, Rückert J, Kati S, Santag S, Schulz TF. 21 April 2017. Kaposi sarcoma herpesvirus (KSHV) latency-associated nuclear antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. PLoS Pathog https://doi.org/10.1371/journal.ppat.1006335
107. Bussey KA, Reimer E, Todt H, Denker B, Gallo A, Konrad A, Ottinger M, Adler H, Sturzl M, Brune W, Brinkmann MM. 2014. The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the Toll-like receptor-induced proinflammatory cytokine response. J Virol 88:9245-9259. https://doi.org/10.1128/JVI.00841-14
108. Ehrlich ES, Chmura JC, Smith JC, Kalu NN, Hayward GS. 2014. KSHV RTA abolishes NFkappaB responsive gene expression during lytic reactivation by targeting vFLIP for degradation via the proteasome. PLoS One 9:e91359. https://doi.org/10.1371/journal.pone.0091359
109. Graham C, Matta H, Yang Y, Yi H, Suo Y, Tolani B, Chaudhary PM. 2013. Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-kappaB activation. J Virol 87:2242-2252. https://doi.org/10.1128/JVI .01393-12
110. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins M. 2003. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116: 3721-3728. https://doi.org/10.1242/jcs.00691
111. Konrad A, Wies E, Thurau M, Marquardt G, Naschberger E, Hentschel S, Jochmann R, Schulz TF, Erfle H, Brors B, Lausen B, Neipel F, Sturzl M. 2009. A systems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation. J Virol 83: 2563-2574. https://doi.org/10.1128/JVI.01512-08
112. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. 2002. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 277:13745-13751. https://doi.org/10 .1074/jbc.M110480200
113. Matta H, Chaudhary PM. 2004. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A 101:9399-9404. https://doi.org/10.1073/pnas .0308016101